PT-141
Also known as: Bremelanotide, Vyleesi
Brand names: Vyleesi
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-141 works through the central nervous system by activating melanocortin receptors involved in sexual arousal. Clinical trials demonstrated significant improvements in sexual desire and satisfaction.
Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity |
| Frequency | As needed |
Common Side Effects
Serious Side Effects
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy
- Breastfeeding
Evidence Quality
Clinical Trial Phase
Approved (post-market)
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| PT-141 | $800 - $1200/mo | FDA Approved |
| Melanotan II | $30 - $60/mo | Not submitted |
Where to get PT-141
Prescription telehealth partners - see pricing and eligibility.
PeptideVS may earn a commission from providers listed below. Our editorial data is independent - see our disclosure for details.
PlushCare
Sponsored
Primary-care telehealth with broad Rx coverage and same-day appointments.
- Broad primary-care scope, not GLP-1-only
- Same-day video visits in all 50 states
- Works with insurance for most plans
We may earn a commission when you sign up.
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.